دورية أكاديمية

Monocyte Subsets and Serum Inflammatory and Bone-Associated Markers in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma

التفاصيل البيبلوغرافية
العنوان: Monocyte Subsets and Serum Inflammatory and Bone-Associated Markers in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma
المؤلفون: Daniela Damasceno, Julia Almeida, Cristina Teodosio, Luzalba Sanoja-Flores, Andrea Mayado, Alba Pérez-Pons, Noemi Puig, Paula Arana, Bruno Paiva, Fernando Solano, Alfonso Romero, Sergio Matarraz, Wouter B. L. van den Bossche, Juan Flores-Montero, Brian Durie, Jacques J. M. van Dongen, Alberto Orfao
المصدر: Cancers, Vol 13, Iss 6, p 1454 (2021)
بيانات النشر: MDPI AG, 2021.
سنة النشر: 2021
المجموعة: LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
مصطلحات موضوعية: plasma cell neoplasms, MGUS, multiple myeloma, monocytes, FcεRI monocytes, tumor microenvironment, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
الوصف: Background. Monocyte/macrophages have been shown to be altered in monoclonal gammopathy of undetermined significance (MGUS), smoldering (SMM) and active multiple myeloma (MM), with an impact on the disruption of the homeostasis of the normal bone marrow (BM) microenvironment. Methods: We investigated the distribution of different subsets of monocytes (Mo) in blood and BM of newly-diagnosed untreated MGUS (n = 23), SMM (n = 14) and MM (n = 99) patients vs. healthy donors (HD; n = 107), in parallel to a large panel of cytokines and bone-associated serum biomarkers. Results: Our results showed normal production of monocyte precursors and classical Mo (cMo) in MGUS, while decreased in SMM and MM (p ≤ 0.02), in association with lower blood counts of recently-produced CD62L+ cMo in SMM (p = 0.004) and of all subsets of (CD62L+, CD62L− and FcεRI+) cMo in MM (p ≤ 0.02). In contrast, intermediate and end-stage non-classical Mo were increased in BM of MGUS (p ≤ 0.03), SMM (p ≤ 0.03) and MM (p ≤ 0.002), while normal (MGUS and SMM) or decreased (MM; p = 0.01) in blood. In parallel, increased serum levels of interleukin (IL)1β were observed in MGUS (p = 0.007) and SMM (p = 0.01), higher concentrations of serum IL8 were found in SMM (p = 0.01) and MM (p = 0.002), and higher serum IL6 (p = 0.002), RANKL (p = 0.01) and bone alkaline phosphatase (BALP) levels (p = 0.01) with decreased counts of FcεRI+ cMo, were restricted to MM presenting with osteolytic lesions. This translated into three distinct immune/bone profiles: (1) normal (typical of HD and most MGUS cases); (2) senescent-like (increased IL1β and/or IL8, found in a minority of MGUS, most SMM and few MM cases with no bone lesions); and (3) pro-inflammatory-high serum IL6, RANKL and BALP with significantly (p = 0.01) decreased blood counts of immunomodulatory FcεRI+ cMo-, typical of MM presenting with bone lesions. Conclusions: These results provide new insight into the pathogenesis of plasma cell neoplasms and the potential role of FcεRI+ cMo in normal bone homeostasis.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 2072-6694
Relation: https://www.mdpi.com/2072-6694/13/6/1454; https://doaj.org/toc/2072-6694
DOI: 10.3390/cancers13061454
URL الوصول: https://doaj.org/article/a40a6b6b31954488b86a57e8cb34cb58
رقم الأكسشن: edsdoj.40a6b6b31954488b86a57e8cb34cb58
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:20726694
DOI:10.3390/cancers13061454